Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in USD (TTM)187.41m
- Net income in USD-817.84m
- Incorporated1998
- Employees648.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GH Research PLC | 0.00 | -11.36m | 568.59m | 9.00 | -- | 2.16 | -- | -- | -0.3588 | -0.3588 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -4.06 | -- | -4.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,963.23 | -- | -- | -- |
| Inhibrx Inc | 7.03m | -110.76m | 573.37m | 106.00 | -- | -- | -- | 81.58 | -2.86 | -2.86 | 0.1819 | -0.1261 | 0.042 | -- | 30.56 | 66,301.89 | -66.10 | -- | -76.59 | -- | -- | -- | -1,575.94 | -- | -- | -11.34 | 1.03 | -- | -43.89 | -- | -7.41 | -- | -- | -- |
| Altimmune Inc | 3.48m | -96.94m | 575.07m | 47.00 | -- | 2.80 | -- | 165.48 | -2.24 | -2.24 | 0.0792 | 4.20 | 0.0149 | -- | 1.49 | 73,940.85 | -41.50 | -46.03 | -43.64 | -49.30 | -- | -- | -2,789.38 | -636.31 | -- | -- | 0.00 | -- | -46.12 | 6.39 | -97.96 | -- | 123.54 | -- |
| Nektar Therapeutics | 96.34m | -524.81m | 577.21m | 740.00 | -- | 1.26 | -- | 5.99 | -2.83 | -2.83 | 0.5195 | 2.45 | 0.0863 | 1.39 | 4.96 | 130,185.10 | -47.00 | -8.21 | -52.55 | -9.10 | 77.26 | 93.55 | -544.77 | -30.80 | 6.18 | -93.45 | 0.00 | -- | -33.36 | -9.24 | -17.86 | -- | 18.58 | -- |
| Nurix Therapeutics Inc | 38.70m | -154.47m | 580.03m | 242.00 | -- | 2.08 | -- | 14.99 | -3.46 | -3.46 | 0.8672 | 5.92 | 0.0848 | -- | 30.51 | 159,921.50 | -33.86 | -- | -38.97 | -- | -- | -- | -399.14 | -- | -- | -- | 0.00 | -- | 66.95 | -- | -171.02 | -- | -- | -- |
| Adicet Bio Inc | 33.89m | -47.75m | 588.04m | 86.00 | -- | 1.88 | -- | 17.35 | -1.37 | -1.37 | 0.8926 | 7.33 | 0.1132 | -- | 24.99 | 394,034.90 | -15.95 | -44.35 | -17.01 | -49.25 | -- | -- | -140.90 | -914.88 | -- | -- | 0.00 | -- | -45.65 | -- | -69.04 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -56.37m | 591.11m | 42.00 | -- | 1.89 | -- | -- | -1.14 | -1.14 | 0.00 | 4.95 | 0.00 | -- | -- | 0.00 | -20.10 | -- | -20.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.03 | -- | -- | -- |
| Nkarta Inc | 0.00 | -98.08m | 593.92m | 127.00 | -- | 1.41 | -- | -- | -2.77 | -2.77 | 0.00 | 8.69 | 0.00 | -- | -- | 0.00 | -24.13 | -- | -24.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.79 | -- | -- | -- |
| Morphosys Ag (ADR) | 187.41m | -817.84m | 594.09m | 648.00 | -- | -- | -- | 3.17 | -5.99 | -5.99 | 1.37 | -0.1931 | 0.0955 | 2.22 | 1.79 | 256,023.00 | -41.67 | -- | -47.78 | -- | 78.40 | -- | -436.39 | -- | 2.91 | -4.03 | 1.09 | -- | -45.19 | -- | -625.55 | -- | -- | -- |
| NanoString Technologies Inc | 142.90m | -139.26m | 597.91m | 766.00 | -- | 5.31 | -- | 4.18 | -3.03 | -3.03 | 3.11 | 2.42 | 0.3085 | 1.93 | 4.50 | 186,558.80 | -30.06 | -25.11 | -33.50 | -29.46 | 52.53 | 61.78 | -97.45 | -57.30 | 6.04 | -19.72 | 0.6672 | -- | 23.67 | 10.90 | -4.70 | -- | 16.72 | -- |
| Mersana Therapeutics Inc | 6.34m | -193.93m | 598.56m | 169.00 | -- | 4.47 | -- | 94.38 | -2.45 | -2.45 | 0.0794 | 1.38 | 0.0251 | -- | -- | 37,526.63 | -76.65 | -52.20 | -98.42 | -70.47 | -- | -- | -3,057.88 | -547.25 | -- | -86.75 | 0.156 | -- | -94.81 | -72.04 | -93.15 | -- | -9.78 | -- |
| Caribou Biosciences Inc | 13.39m | -85.24m | 598.67m | 97.00 | -- | 1.72 | -- | 44.70 | -1.41 | -1.41 | 0.2217 | 5.72 | 0.0462 | -- | 7.77 | 138,061.90 | -29.40 | -- | -32.48 | -- | -- | -- | -636.48 | -- | -- | -- | 0.00 | -- | -22.35 | -- | -95.07 | -- | -- | -- |
| Ideaya Biosciences Inc | 29.15m | -65.86m | 602.82m | 91.00 | -- | 1.83 | -- | 20.68 | -1.71 | -1.71 | 0.7593 | 6.96 | 0.0875 | -- | 36.14 | 359,851.80 | -19.77 | -- | -23.01 | -- | -- | -- | -225.96 | -- | -- | -- | 0.00 | -- | 43.01 | -- | -44.26 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -211.46m | 603.08m | 412.00 | -- | 1.31 | -- | -- | -1.64 | -1.64 | 0.00 | 3.54 | 0.00 | -- | -- | 0.00 | -34.07 | -- | -36.02 | -- | -- | -- | -- | -- | -- | -205.27 | 0.0968 | -- | -100.00 | -- | -315.48 | -- | -- | -- |
| Cerus Corporation | 182.84m | -42.23m | 614.50m | 294.00 | -- | 8.11 | -- | 3.36 | -0.2428 | -0.2428 | 1.05 | 0.4279 | 0.8317 | 2.54 | 7.36 | 621,904.80 | -19.21 | -37.07 | -28.77 | -52.37 | 59.06 | 61.16 | -23.10 | -61.35 | 1.73 | -5.86 | 0.4761 | -- | 39.62 | 32.35 | 9.16 | -- | 10.08 | -- |
Data as of Sep 28 2022. Currency figures normalised to MorphoSys AG's reporting currency: US Dollar USD
1.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 30 Jun 2022 | 912.90k | 0.67% |
| Hudson Bay Capital Management LPas of 30 Jun 2022 | 870.00k | 0.64% |
| LifeSci Fund Management LLCas of 30 Jun 2022 | 185.00k | 0.14% |
| Morgan Stanley & Co. LLCas of 30 Jun 2022 | 175.53k | 0.13% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2022 | 131.23k | 0.10% |
| Tekla Capital Management LLCas of 30 Jun 2022 | 81.87k | 0.06% |
| Optiver US LLCas of 30 Jun 2022 | 70.31k | 0.05% |
| Aperio Group LLCas of 30 Jun 2022 | 58.36k | 0.04% |
| Candriam Belgium SAas of 30 Jun 2022 | 58.17k | 0.04% |
| Old Mission Capital LLCas of 30 Jun 2022 | 40.46k | 0.03% |
More ▼
Data from 30 Jun 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
